Oral Microbiome Stamp in Alzheimer's DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared the oral microbiome of Alzheimer's disease (AD) patients (n = 64) to cognitively healthy seniors (n = 71) in Central Asia. They used 16S ribosomal RNA sequencing to characterize bacterial taxonomic composition in each group.
How was it studied?
This was a case-control study. Oral samples were sequenced and analyzed for taxonomic composition, diversity, and functional metabolic pathways, then compared between the AD and healthy groups. A separate region-based analysis compared oral microbiome differences within the AD cohort.
What did they find?
The AD group had higher overall microbial diversity, with an increase in Firmicutes and a decrease in Bacteroidetes compared to healthy seniors. LEfSe analysis identified distinct genus-level differences between groups, and periodontitis-associated bacteria were decreased in the AD group. Metabolic pathway distributions also differed notably between the two groups, though bacterial richness and functional differences were absent in the region-based comparison.
Why it matters
The findings support a link between periodontal disease, oral microbiome alterations, and Alzheimer's disease. The authors note that a complete picture of oral microbiome composition in AD still requires further investigation.